The advancement of personalized medicine in oncology has driven the development of diagnostic tests that detect genomic alterations which can be specifically targeted by therapeutic molecules. Alongside molecular approaches, Immunohistochemistry (IHC) plays a vital role in establishing a definitive diagnosis, minimizing subjective variations, and guiding the initiation of personalized treatment strategies.
IHC is a technique used to detect specific antigens in tissue sections or smears, based on the affinity between an antibody and its corresponding antigen.
At Ashok Laboratory, we offer a comprehensive panel of IHC markers. When required, two complementary IHC marker tests may be performed at the discretion of the reporting histopathologist to ensure diagnostic accuracy. The department is NABL accredited, ensuring compliance with the highest standards of quality and reliability.
Our Facilities:
- Determine cancer sub-type and guide personalized drug selection
- Identify tumor types such as carcinoma, sarcoma, lymphoma, or mixed tumors (e.g., carcinosarcoma, adeno-squamous carcinoma)
- Accurately determine the origin of a tumor (primary or metastatic), even in undifferentiated cases
- Identify carcinoid (neuroendocrine) tumors
- Assist in clinical management of specific cancers: breast cancer (ER, Ki-67), malignant melanoma (VEGF), head and neck cancer (p63)
- Diagnose hematolymphoid proliferations, essential for treatment planning
- Monitor cancer progression and provide predictive and prognostic insight
- Consulting pathologists available to address patient or clinician queries
- Breast Cancer Comprehensive Panel – ER, PR, HER2
- Breast Cancer Extended Panel – ER, PR, HER2, Ki-67
Report Delivery:
Turnaround time varies by test. Status updates are shared via WhatsApp alerts. Reports are available through email, WhatsApp, or as hard copies at reception. Free home delivery is also provided.
